Millipore Sigma Vibrant Logo

Best practices: Nucleic acid removal from vaccine processes

Issue: June 24, 2014
| Category: Upstream, Downstream




The production of viral vaccines at commercial scale requires large quantities of viruses as an antigenic source. Because host cell residuals can be found in the final product, nucleic acids in particular, there is the chance of transfer and integration of these nucleic acids into the living cell's genetic material. This can potentially lead to harmful effects, including cancer.

Health authorities and regulatory bodies continue to increase safety standards for biopharmaceutical products, providing stringent guidelines on the removal of residual nucleic acids from vaccine manufacturing. Several physiochemical methods exist to reduce nucleic acid during these processes, each with its unique strengths and weaknesses.

Merck has conducted studies on different methods to efficiently remove nucleic acids from the vaccine process. In particular, we focused on using Benzonase® endonuclease, a very effective biochemical method to remove DNA and RNA in laboratory and industrial scale processes as well as several other bioprocessing technologies.

To learn more about Benzonase® endonuclease and how it offers many advantages over existing methods of nucleic acid removal, watch our recent webinar and read our article.

To watch, please click here

In This Same Issue:

Recent Articles

Article Search

Article Archives

Events

Webinars